2BBBullish & Bearish
Definium Therapeutics, Inc. (DFTX) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 43 out of 100.
Definium Therapeutics (formerly MindMed) is a biotech company forging a new era of psychiatry by applying precision to psychedelic medicine. We develop science-led, accessible treatment approaches designed to open new routes for brain health and help people reclaim more vibrant lives.
Definium Therapeutics, Inc.’s current 2BB score is 43 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 49 | Moderate |
| Momentum | 50 | Stable |
| Financial strength | 14 | Very Weak |
| Quality | 92 | Very Strong |
| Risk | 23 | Low (provisional) |
| CEO | Robert Barrow |
| Founded | 2010 |
| Employees | 106 |
| 52-week range | $14.62 – $49.70 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-05-05 | — | -0.5456 | — | $0.00 |
| 2027-02-24 | — | -0.5488 | — | $0.00 |
| 2026-11-09 | — | -0.5683 | — | $0.00 |